ESTRO 2024 - Abstract Book

S1861

Clinical - Mixed sites, palliation

ESTRO 2024

This study demonstrated a favorable toxicity profile for the combination of targeted therapies and radiation therapy in cancer treatment. The dataset shows low toxicity across all irradiated regions and TT types, even when considering patients who received multiple rounds of radiation. The study acknowledges some limitations, including the impact of the COVID-19 pandemic on follow-up assessments, potential underreporting of side effects, and interobserver variability in toxicity evaluation. However, severe (grade 3 or higher) toxicities were conspicuously absent. Fatigue, dyspnea and dry cough were the most common side effects, but they were generally not more pronounced than what is typically observed in patients receiving RT alone. The findings suggest the safe administration of TT combined with RT, with low risks of severe complications. Effective side effect management played a role in these outcomes. Further research is needed to fully understand the long-term effects and tolerability of TT in combination with RT.

Keywords: Combination of Targeted Therapies and Radiotherapy

631

Poster Discussion

Stereotactic ablative radiotherapy for oligoprogressive tumours: systematic review and meta-analysis

Vivian S Tan 1 , Jerusha Padayachee 2 , George B Rodrigues 1 , Inmaculada Navarro 2 , Prakesh S Shah 3 , David A Palma 1 , Aisling Barry 4 , Rouhi Fazelzad 5 , Jacques Raphael 6 , Joelle Helou 1 1 London Regional Cancer Center, Department of Radiation Oncology, London, Canada. 2 Princess Margaret Cancer Center, Department of Radiation Oncology, Toronto, Canada. 3 Mount Sinai Hospital, Departments of Paediatrics, Toronto, Canada. 4 Cork University Hospital, Department of Radiation Oncology, Cork, Ireland. 5 Princess Margaret Cancer Center, Library and Information Services, Toronto, Canada. 6 London Regional Cancer Center, Department of Medical Oncology, London, Canada

Purpose/Objective:

The treatment of metastatic solid tumours has undergone a shift in practice towards an increased use of stereotactic ablative radiotherapy (SABR) over the past decade. Randomized trials have supported the role of SABR in the treatment of oligometastatic disease [1 – 5] and more recently there has been an increased interest in exploring its role in the “oligoprogressive (OP) state” [6– 8]. Published studies are mostly retrospective and have frequently included a small sample size and different tumour types, histologies and indications, making it challenging to tease out the true effectiveness of such an approach for specific tumour types and clinical situations.

Herein we aim to review the evidence and to pool oncologic outcomes from available studies to assess the effectiveness of SABR in patients treated for oligoprogressive metastases.

Material/Methods:

The systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO CRD42022166973). MEDLINE ALL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, EMBASE, all from the OvidSp platform, and Web of Science from Clarivate were searched from January